Affiliation:
1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Abstract
Key Points
Checkpoint inhibition use before alloBMT followed by PTCy is not associated with increased aGvHD or transplant-related mortality/morbidity. Prior checkpoint inhibitor therapy should not be a contraindication to allogeneic transplantation, especially in the setting of PTCy.
Publisher
American Society of Hematology
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献